Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.

AI/ML

Biotechnology

Health Care

Pharmaceutical

Iktos

Yann Gaston-Mathe

Mac Monson

Charles-Henry Dion

Marion Laguette

Nicolas Martin, PharmD PhD

Kevin Mollenhauer

Quentin Perron

Nicolas Do Huu, PhD

Stéphane MILOT

Jean-Christophe Meillon

Franck Le Vaillant

Alexis Denis

El Gasser Abderraouf

Iktos

Org chart

Similar companies